Category: Patents

MEwens
We’ve written about some of the most common consumer questions about the newly launched generic version of Pfizer’s cholesterol-lowering Lipitor.
One remaining question is how much money will be saved from the generic iterations of the name-brand blockbuster — the U.S. sales of which were $7.8 billion in the year ended Sept. 30, according […]

MEwens
Health Suit Complication?: A small-business owner who is a key plaintiff in the 26-state suit against the Obama health-care law has closed her business and filed for bankruptcy, which may complicate her legal standing to be part of the suit, the WSJ reports. The suit relied in part on the financial burden the […]

MEwens
Pfizer is hoping to milk even more dollars from its blockbuster Lipitor by introducing an over-the-counter version of the cholesterol-lowering drug, the WSJ reports, citing people familiar with the matter.
Whether Pfizer can get the FDA to swallow an OTC statin is another matter entirely. The WSJ reports the company would first need to […]

MEwens
Patent Defense: Pfizer goes to court this week to try to extend its exclusive rights to sell Viagra — which has U.S. sales of $1 billion per year — until 2019, the WSJ reports. Pfizer’s basic patent on the drug, which was first developed to treat heart-related issues, expires next year, but the […]

Jonathan D. Rockoff
During its third-quarter earnings call today, big PBM Medco Health Solutions gave its new 10-year projections on the generics pipeline, with not-so-muted glee.
Read more this great post here

JGrimes
These look to be good times for the generic drug makers. Copycat drugs accounted for 75% of the U.S. prescription drug volume last year, up from 57% just five years ago, data tracker IMS Health reported just last week.
All well and good, but even with billions in potential sales coming available as branded […]

JGrimes
The Orphan Drug Act has been around since 1983 offering tax incentives and competition protection for drugs aimed at treating rare diseases. But there have been relatively few orphan drugs developed, so the FDA is beating the bushes for more participation.
FDA staffers recently ran a two-day workshop in Claremont, Calif., to help drug […]

noreply@blogger.com (RCoffield@fsblaw.com)
India has become a hot market for multinational drug companies since it revised its patent laws to give more protection to brand-name medicine. But to hear the branded makers tell it, the patent welcome mat has some holes in it, a WSJ report recounts this morning.
The drug makers point to three top-selling […]

noreply@blogger.com (RCoffield@fsblaw.com)
A bunch of the blockbuster drugs that carried the drug industry for the past decade are about to go off patent. As we’ve noted along with everybody else, that’s going to be tough for pharma companies.
(See, for example, the news this week from Pfizer and Bristol-Myers Squibb, which over the next two […]

noreply@blogger.com (RCoffield@fsblaw.com)
Patent deals between generic and branded drug makers have been getting lot of attention lately on both sides of the Atlantic. Today, Pfizer took a turn in the spotlight.
The world’s largest pharma company said it was among those asked Tuesday by European regulators to disclose their patent agreements with generic makers. Pfizer […]